Canadian study suggests it’s time to rethink how we treat atrial fibrillation

A national study led by University of British Columbia (UBC) researchers at the Centre for Cardiovascular Innovation is shedding light on how to more effectively treat atrial fibrillation (AF)—a common heart rhythm problem associated with increased risk of stroke and heart failure. The study, published today in the New England Journal of Medicine, shows that […]

Continue Reading

Biases in cardiometabolic research put minority women’s lives at risk

Biases in heart disease and metabolic disorder studies—also known as cardiometabolic studies—are putting the lives of midlife Black and Hispanic women in jeopardy. These women are experiencing cardiometabolic risks five to 11 years earlier than white women, but studies designed to gauge these differences often underestimate the disparity, according to new research from the University […]

Continue Reading

New medicine reduces triglyceride by 25%, no change in CVD risk in people with type 2 diabetes

A new medication, pemafibrate, lowered triglyceride levels among adults with type 2 diabetes yet did not decrease their cardiovascular risk, according to late-breaking science research presented today at the American Heart Association’s Scientific Sessions 2022.“Triglyceride levels are commonly measured as part of routine preventive care in the U.S. Understanding the best course of treatment for […]

Continue Reading

Maximizing heart failure meds within 2 weeks reduces risk of hospital readmission, death

Ramping up medication doses quickly after being hospitalized for acute heart failure resulted in a lower risk of dying or being readmitted for heart failure within the first six months after discharge, compared to usual care, according to a featured science research presentation today at the American Heart Association’s Scientific Sessions 2022. Millions of people […]

Continue Reading